Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Overexpression of programmed death‐1 (PD‐1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD‐1‐blocking antibody that inhibits the PD‐1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Maruyama, Dai, Hatake, Kiyohiko, Kinoshita, Tomohiro, Fukuhara, Noriko, Choi, Ilseung, Taniwaki, Masafumi, Ando, Kiyoshi, Terui, Yasuhito, Higuchi, Yusuke, Onishi, Yasushi, Abe, Yasunobu, Kobayashi, Tsutomu, Shirasugi, Yukari, Tobinai, Kensei
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448600/
https://ncbi.nlm.nih.gov/pubmed/28267244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13230
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge